News | Cardiovascular Ultrasound | June 15, 2022

Cardiawave Confirms the Safety of VALVOSOFT its Non-Invasive Ultrasound Treatment for Aortic Stenosis

Successful completion of the FIM II clinical study prior to the pivotal study, that will pave the way for CE marking

Cardiawave SA, a deeptech medical device manufacturer that has developed Valvosoft, a revolutionary non-invasive medical device to treat aortic stenosis, the most prevalent heart valve disease in adults, today announced positive MRI scans before and after therapeutic ultrasound treatment to assess the risk of stroke

June 15, 2022 — Cardiawave SA, a deeptech medical device manufacturer that has developed Valvosoft, a revolutionary non-invasive medical device to treat aortic stenosis, the most prevalent heart valve disease in adults, today announced positive MRI scans before and after therapeutic ultrasound treatment to assess the risk of stroke.

This final phase of the clinical study “Valvosoft FIM STUDY” (FIM II) showed no signs of any cerebral vascular anomaly in the 10 patients treated. This marks the completion of two successful First-In-Human clinical studies involving a total of 40 patients treated in France, the Netherlands and Serbia.

“This confirmation of the safety of Valvosoft bodes well for the launch of patient recruitment for our European pivotal study which will commence shortly in France, and extended to Germany and the Netherlands, with the aim of obtaining CE Marking.” said Benjamin Bertrand, CEO of Cardiawave.

Valvosoft’s non-invasive treatment brings great hope for patients with aortic stenosis and for their families. Having the absence of any abnormality before and after treatment being confirmed by MRI scans is major clinical step forward” declared Professeur Emmanuel Messas the Georges Pompidou European Hospital (AP-HP), in Paris.

For more information: www.cardiawave.com

 

Related Content

Feature | Cardiac Imaging | By Ronny Shalev, Ph.D.

Artificial intelligence’s (AI) applicability in cardiac imaging is rapidly growing and was a major topic of discussion ...

Home June 28, 2022
Home
News | Cardiac Imaging

June 24, 2022 — The Radiological Society of North America (RSNA) reports that Coronary Artery Calcium (CAC) scoring with ...

Home June 24, 2022
Home
News | Cardiac Imaging

June 23, 2022 — New research from the Smidt Heart Institute at Cedars-Sinai shows for the first time that the path ...

Home June 23, 2022
Home
News | Cardiac Imaging

May 2, 2022 — According to ARRS’ American Journal of Roentgenology (AJR), routine visual ordinal coronary artery calcium ...

Home May 02, 2022
Home
News | Cardiac Imaging

April 11, 2022 — Radiation to the heart during treatment for locally advanced lung cancer is associated with an ...

Home April 11, 2022
Home
News | Cardiac Imaging
February 21, 2022 – Acute coronary syndromes (such as heart attacks) and strokes are a leading cause of morbidity and ...
Home February 21, 2022
Home
News | Cardiac Imaging
February 21, 2022 – Researchers at Michigan Medicine have found a novel method of measuring growth in the body’s largest ...
Home February 21, 2022
Home
News | Cardiac Imaging

February 18, 2022 — GE Healthcare has announced that it has received approval from the European Medicines Agency (EMA) ...

Home February 18, 2022
Home
Videos | Cardiac Imaging

Interview with Campbell Rogers, M.D., chief medical officer of HeartFlow which has developed a CT image-based fractional ...

Home February 01, 2022
Home
Videos | Cardiac Imaging

American Society of Nuclear Cardiology (ASNC) President Dennis Calnon, M.D., MASNC, FASE, FSCCT, director of cardiac ...

Home February 01, 2022
Home
Subscribe Now